NEW YORK (Reuters) - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment, companies and industry experts said.
from Reuters: Science News http://ift.tt/1Vo4yye
via IFTTT
No comments:
Post a Comment